Novartis-MIT Center decries decades-old drug manufacturing processes

The traditional, small-molecule pharma company invests a "shockingly low" portion of its capital in product development, says Bernhardt Trout, director at the Novartis-MIT Center for Continuous Manufacturing. Basic manufacturing technologies have not changed for decades. Trout and others spoke recently at an MIT roundtable discussion on the future of manufacturing.

Trout suggested a streamlined drug-approval process would help motivate industry innovation.

The FDA, of course, has acknowledged the same. Its planned restructuring is a strategy aimed at getting drugs out of the lab and to patients more quickly.

But those at the MIT event have additional ideas. Among them: nanotechnology. Advocates are clear that the technology holds promise to improve drug-making as well as the making of other kinds of products. And they admit that expertise and the technology tools needed to develop nano-manufacturing tools are among the current stumbling blocks.

But looking past these immediate--and ultimately solvable--problems looms a larger one: integrating nanotechnology with manufacturing processes. So says Martin Culpepper, a nanotech manufacturing toolmaker. Culpepper, an MIT associate professor of mechanical engineering, likens his lab to an apprenticeship. "It takes a long time to learn how to do this stuff properly," he says in Azonano.com.

Culpepper and Trout agree that advances in academic research are especially critical to move industry.

- read the article for more

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.